Literature DB >> 25680277

Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.

Douglas H Yamada1, Heidi Elsaesser1, Anja Lux2, John M Timmerman3, Sherie L Morrison1, Juan Carlos de la Torre4, Falk Nimmerjahn2, David G Brooks5.   

Abstract

Understanding how viruses subvert host immunity and persist is essential for developing strategies to eliminate infection. T cell exhaustion during chronic viral infection is well described, but effects on antibody-mediated effector activity are unclear. Herein, we show that increased amounts of immune complexes generated in mice persistently infected with lymphocytic choriomeningitis virus (LCMV) suppressed multiple Fcγ-receptor (FcγR) functions. The high amounts of immune complexes suppressed antibody-mediated cell depletion, therapeutic antibody-killing of LCMV infected cells and human CD20-expressing tumors, as well as reduced immune complex-mediated cross-presentation to T cells. Suppression of FcγR activity was not due to inhibitory FcγRs or high concentrations of free antibody, and proper FcγR functions were restored when persistently infected mice specifically lacked immune complexes. Thus, we identify a mechanism of immunosuppression during viral persistence with implications for understanding effective antibody activity aimed at pathogen control.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25680277      PMCID: PMC4334737          DOI: 10.1016/j.immuni.2015.01.005

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  49 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

Review 2.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 3.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

Review 4.  Antibodies for HIV treatment and prevention: window of opportunity?

Authors:  M Huber; W C Olson; A Trkola
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

Review 6.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

Review 7.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

Review 8.  Chronic bystander infections and immunity to unrelated antigens.

Authors:  Erietta Stelekati; E John Wherry
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  30 in total

1.  Cutting Edge: B Cell-Intrinsic T-bet Expression Is Required To Control Chronic Viral Infection.

Authors:  Burton E Barnett; Ryan P Staupe; Pamela M Odorizzi; Olesya Palko; Vesselin T Tomov; Alison E Mahan; Bronwyn Gunn; Diana Chen; Michael A Paley; Galit Alter; Steven L Reiner; Georg M Lauer; John R Teijaro; E John Wherry
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

2.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions.

Authors:  Michelle L Miller; Olivera J Finn
Journal:  Methods Enzymol       Date:  2019-08-12       Impact factor: 1.600

4.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

5.  Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation.

Authors:  E Ashley Moseman; Tuoqi Wu; Juan Carlos de la Torre; Pamela L Schwartzberg; Dorian B McGavern
Journal:  Sci Immunol       Date:  2016-10-21

6.  Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.

Authors:  Caroline M Reed; Nicole D Cresce; Ileana S Mauldin; Craig L Slingluff; Walter C Olson
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

7.  Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.

Authors:  Richard J Stopforth; Robert J Oldham; Alison L Tutt; Patrick Duriez; H T Claude Chan; Brock F Binkowski; Chad Zimprich; Dun Li; Philip G Hargreaves; Mei Cong; Venkat Reddy; Maria J Leandro; Geraldine Cambridge; Anja Lux; Falk Nimmerjahn; Mark S Cragg
Journal:  J Immunol       Date:  2018-01-19       Impact factor: 5.422

Review 8.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13.

Authors:  Olga Luft; Ramzi Khattar; Kaveh Farrokhi; Dario Ferri; Nataliya Yavorska; Jianhua Zhang; Hassan Sadozai; Oyedele Adeyi; Andrzej Chruscinski; Gary A Levy; Nazia Selzner
Journal:  Immunology       Date:  2018-02-20       Impact factor: 7.397

Review 10.  Modulating Antibody Functionality in Infectious Disease and Vaccination.

Authors:  Bronwyn M Gunn; Galit Alter
Journal:  Trends Mol Med       Date:  2016-10-15       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.